Centocor is a globally growing force in healthcare. Opening new pathways in medicine, with the needs of patients always our top concern.
Building on our leadership position in monoclonal antibody technology, Centocor creates, acquires and markets unique biopharmaceutical therapies. Our innovative products focus on the management of three major disease areas; cardiovascular, immunological disorders and cancer.
We strive to be a prominent company. Not only by the marketing of important new products. We also effectuate to increase the applications of our existing products. This means investing in the right research, forging the right business partnerships and hiring the right people to maintain the highest quality.
Centocor employees do make the difference. We thrive on challenge. We demand the best. And we take great pride that our products enhance the lives of patients all around the world.
Centocor in Leiden
With approximately 950 employees, Centocor is one of the largest companies in the Leiden region. And most likely one of the most interesting companies, as Centocor has a prominent position in the world of biotechnology. Centocor produces medicines. Not by traditional methods, but by using biopharmaceutical processes. These are new, extremely clean production methods delivering special medicines, with a worldwide indication.
Research and Development
Besides production, Centocor works hard on the development of new medicines. This is mainly done in the United States. The Leiden site and headquarters in the US, coordinate worldwide research into the effectiveness and the safety of the products.
